000			03064cam a2200349 a 4500
003			EG-GiCUC
005			20250223032541.0
008			200816s2019 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.09.08.Ph.D.2019.Ya.P
100	0		_aYasmine Kamal Ramadan
245	1	0	_aProbiotics versus placebo as a prophylaxis to prevent clinical manifestations of oral candidosis in patient's with Sjogren's syndrome / _cYasmine Kamal Ramadan ; Supervised Mahmoud Kandil , Mervat Eissa , Reham Hamed
246	1	5	_aمقارنة التأثير الوقائي للبروبايوتيكس بالدواء الوهمى لمنع المظاهر السريرية للمبيضات الفموية لدى المرضى الذين يعانون من متلازمة چوجرن
260			_aCairo : _bYasmine Kamal Ramadan , _c2019
300			_a138 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Oral and Dental Medicine - Department of Periodontology
520			_aBackground: The prevalence of oral candidosis has been rising in more than 80% in patients with Sjogren{u2019}s syndrome. Probiotics can be considered an alternative approach to antifungal drugs for treatment and prophylaxis of oral candidosis. This study aimed to evaluate the short-term efficacy of Probiotics in reduction of oral Candidal growth in patients with Sjogren's Syndrome. Methods: Thirty-two Sjogren{u2019}s syndrome patients were randomlyallocated in two groupsreceiving either Probiotics or placebo capsules twice daily for 5 weeks. Oral rinse solution samples were collected and Candidal levels were determined(CFU/mL) at baseline and after the 5-week experimental period. Pain, erythema and angular cheilitis were also assessed at baseline, 2, 4 and 5-weeks. Results: In the probiotic group there was a statistically significant reduction of candidal load from baseline to 5th week respectively [median 1950 CFU/ml ,interquartile range, 950 ; 4200 CFU/ml, ; median 999 CFU/ml ,interquartile range, 275 to 1925 CFU/ml, P{u2264} 0.005 ] While the change in candidal load at the same time period in the placebo group was not statistically significant [baseline median 1050 CFU/ml ,interquartile range, 1100 to 4750 CFU/ml ; 5th week median 1150 CFU/ml ,interquartile range, 849 to 3425 CFU/ml, P {u2265}0.005]. Conclusion: The probiotic product containing, L. acidophilus, L. bulgaricus, Streptococcus thermophilus and B. bifidumcan reduce Candidalgrowth in Sjogren's syndrome patients suggesting that this multispecies probiotic can prevent oral candidiasis
530			_aIssued also as CD
653		4	_aOral candidiasis
653		4	_aProbiotics
653		4	_aProphylaxis
700	0		_aMahmoud Kandil , _eSupervisor
700	0		_aMervat Eissa , _eSupervisor
700	0		_aReham Hamed , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c77223 _d77223